2026년 아젠다
Cambridge Venture, Innovation & Partnering (VIP) 주최 제3회
Bio-IT World Venture, Innovation & Partnering
Connect Capital and Science to Shape the Future
자본과 과학을 연결하고, 미래를 형성
2026년 5월 19일
제25회 Bio-IT World Conference & Expo의 일환으로, 제3회 Bio-IT World Venture, Innovation & Partnering Conference(2026년 5월 19일)는 바이오테크놀러지와 정밀의료의 차세대를 촉진하는 투자자·기업 리더·기업가용으로 이그제큐티브 레벨 플랫폼을 제공합니다. 이 소규모 이벤트에서는 벤처캐피털, 사모펀드, 기업 벤처 부문, 성장 단계 기업, 제약 기업의 경영 임원이 한자리에 모입니다. 2026년 프로그램은 AI 드리븐 Discovery, 플랫폼 투자 모델 vs. 제품 투자 모델, 진화하는 M&A·파트너십 전략, IPO·프라이빗 유동성 경로, 자본 배분을 형성하는 규제 시프트에 초점을 맞춥니다. 세션은 시장 역학, 리스크 조정 후 이익, 확장 가능한 혁신 전략에 관한 명확한 인사이트를 투자자에게 제공하는 것을 목적으로 하고 있습니다. 솔직한 디스커션, 파이어사이드 챗, 감수 패널에 의해 참가자는 자본 배분 방법, 혁신 파이프라인의 방향성, 장기적인 승자 판별 방법을 탐구합니다. 투자자용 의견 교환과 함께 150개 이상의 전시, 11개 과학 트랙, 30개국 이상의 글로벌 파트너에 대한 액세스에 의해 시장의 관점을 넓힐 수 있습니다.
Tuesday, May 19
Registration and Networking Coffee
Organizer's Welcome Remarks
MARKET OVERVIEW: Sponsored Presentation (Opportunity Available)
Funding the Modern Pipeline: Capital Strategy across Biology, Technology, and Informatics
Rebecca Stevenson, CFO, Souffle Thereapeutics
This panel explores how capital is being strategically deployed across biology, technology, and informatics. Panelists will discuss how investors are structuring and targeting funding to support drug discovery.
Leadership at the Cutting Edge: Innovation, Strategy & Biotech’s Next Frontier
Michael Nally, CEO, Generate:Biomedicines
This keynote interview with Mike Nally, CEO of Generate:Biomedicines and CEO-Partner at Flagship Pioneering, explores his leadership in advancing generative biology and programmable protein therapeutics. Since joining in 2021, Nally has driven major partnerships, financing-rounds exceeding $750 million, and clinical progress, positioning Generate:Biomedicines at the forefront of AI-driven drug discovery.
Networking Coffee Break
Chairperson's Remarks
Driving Innovation Together: The New Rules of VC, Pharma & Industry Leader Collaboration
Rana Lonnen, General Partner, Science Capital
This panel explores how venture capital, pharma, and industry leaders are reshaping collaboration to accelerate biotech innovation. Panelists will discuss new approaches to funding, partnerships, and technology adoption that drive drug discovery, scale emerging companies, and create more effective pathways from lab-to-market.
Sponsored Presentation (Opportunity Available)
Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective problem-solving session, and participate in active idea sharing.
Innovation in Science & Business Models Advancing Drug Discovery
William T. Mayo, Founder, Wellfleet Advisors
This panel brings together leaders from pharma, biotech, AI, and venture investing to explore how innovative science and business models are transforming drug discovery. Panelists will share insights on leveraging advanced technologies, data-driven R&D, and strategic partnerships to accelerate pipeline development, scale emerging companies, and create new investment opportunities-providing actionable takeaways for investors, entrepreneurs, and CEOs driving the next wave of drug discovery innovation.
Sponsored Presentation (Opportunity Available)
Engineering Access: Scalable Genomics, Technology & the Future of Medicine
Michael Chambers, Founding CEO, Aldevron
This keynote fireside will spotlight the leadership journey behind building and scaling one of genomic medicine’s most critical infrastructure companies. From founding a university lab start-up to leading its growth into a global platform powering cell and gene therapies and a landmark $9.6 billion exit, the conversation will unpack the decisions, discipline, and long-term strategy required to scale enduring biotech-companies in a capital-intensive market.The discussion will conclude with Morgan and Michael highlighting where they see the greatest opportunities in biotech today and providing a forward-looking perspective on the problems to be solved and areas of significant unmet clinical need.
At the Helm: Emerging and Established CEOs in Debate on Building Companies
Joanne L. Viney, PhD, Co-Founder & President & CEO, Seismic Therapeutic
This panel brings together accomplished CEOs from biotech, digital biology, and drug discovery companies for a dynamic debate on building and scaling innovative organizations. Panelists will explore leadership challenges, strategic decision-making, and balancing growth with innovation, offering investors, entrepreneurs, and executives practical insights into what it takes to lead successful companies across the life sciences and tech-enabled drug discovery landscape.
Sponsored Presentation (Opportunity Available)
The Future of Lab Funding: Building Stronger Pathways between Academia, Capital, and Spinouts
Michael Langer, Co-Founder and Managing Partner, T.Rx Capital
As biotech and precision medicine converge with advanced technology, the next generation of breakthrough companies is being born in academia. This executive-level discussion explores how investors, foundations, and institutions can unlock novel university science, modernize lab funding models, and build scalable pathways from discovery to venture-backed spinout, aligning capital, talent, and strategy to accelerate impact in drug discovery.
PLENARY KEYNOTE PROGRAM
Rare Conversations: Explorations of the Research, Funding, and Advocacy for Rare Diseases
Catherine Brownstein, PhD, Manager, Molecular Genomics Core Facility, Boston Children's Hospital; Scientific Director, Manton Center for Orphan Disease Research Gene Discovery Core; Assistant Professor, Harvard Medical School
In a unique plenary series of intimate conversations, we will explore the models, drivers, and challenges facing rare disease research. By uniting leaders in precision medicine, bioinformatics, national rare-disease infrastructure, and real-world legislative advocacy, we will give attendees an expansive, cross-disciplinary view of what’s required to deliver faster, more accurate, and more equitable rare-disease cures.
Welcome Reception in the Exhibit Hall with Poster Viewing
The Bio-IT Kickoff Reception is a reunion-reconnect with friends, explore cutting-edge research, and celebrate innovation! Enjoy poster presentations, networking, and vote for the Best of Show and Poster awards.
Close of Summit
Close of Day
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.